West Pharmaceutical Services, Inc.

NYSE:WST

Medical - Instruments & Supplies

Healthcare
$404.02 +1.56%

+$5.04 today

Market cap
$28.14B
Beta
1.18
P/E (TTM)
43.6
EPS (TTM)
$7.54
Dividend yield
0.26%
52W Low $206.80High $336.82

Volume 0.59M

Average 0.85M

WST Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

West Pharmaceutical Services, Inc.NYSE: WST

Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Investing cash flow declines year over year

Q2 FY2026 investing cash flow of $43.2M (cash outflow) fell 42.6% year over year, behind the -32.4% change in trailing-twelve-month investing cash flow. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Investing cash flow amounted to 9.3% of revenue in FY2025, down 3.8 pp from a year earlier.
  • Investing cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -42.6% toward the trailing-twelve-month pace of -32.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$43.2M+1.2% QoQ
Last fiscal yearDec 2025
-$285.9M-24.5% YoY
LTMJun 2026
-$225.3M-32.4% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.6%——
1 year-24.5%——
3-year CAGR-0.3%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(285.9M) USD
Year-over-year change
+24.5%

Investing Cash Flow vs competitors

How WST compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.4% is the 2nd highest of 5, against a peer median of -101.7%.
  • Investing cash flow amounts to 6.8% of revenue for WST, versus a peer median of 15.4%.
WST Competitors
Investing Cash Flow for WST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATRAptarGroup, Inc.LTM Jun 2026$325.43M USD-13.9%+3.8%8.3%
STVNStevanato Group S.p.A.LTM Jun 2026€275.23M EUR-37.5%+2.6%22.5%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$225.3M USD-32.4%-0.3%6.8%
ICUIICU Medical, Inc.LTM Jun 2026$79.77M USD-165.8%—3.7%
BLFSBioLife Solutions, Inc.LTM Mar 2026$46.19M USD-247.4%+7.2%46.3%
Peer median (excluding WST) —-101.7%+3.8%15.4%

Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income661.8M585.9M593.4M492.7M493.7M
Depreciation & Amortization122.3M120.6M137.3M155.4M171.4M
Deferred Income Tax(42.9M)(30.8M)37.5M0(13.7M)
Stock-Based Compensation37.5M23.7M23.3M18.7M23.8M
Change in Working Capital(193.8M)(15M)(20.4M)2.9M79.8M
Accounts Receivables(123.5M)(35.6M)4M(58.8M)6.9M
Inventory(86.5M)(49.8M)(13.5M)42M(62.8M)
Accounts Payables16.8M(2.8M)4.4M2.9M17.9M
Other Working Capital(600K)73.2M(15.3M)16.8M117.8M
Other Non-Cash Items(900K)36.1M5.4M(16.3M)(200K)
Operating Cash Flow584M724M776.5M653.4M754.8M
Capital Expenditures(253.4M)(284.6M)(362M)(377M)(285.9M)
Acquisitions (Net)(2.2M)0000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities2.5M(3.6M)(6.7M)(1.7M)0
Investing Cash Flow(253.1M)(288.2M)(368.7M)(378.7M)(285.9M)
Debt Repayment(2.2M)(44.3M)(2.3M)(27.6M)(1.1M)
Common Stock Issued000018.2M
Common Stock Repurchased(151.9M)(222.2M)(451.2M)(566.6M)(134M)
Dividends Paid(51.1M)(54.1M)(57M)(59.1M)(61.2M)
Other Financing Activities37.1M27M50.9M30.7M(7M)
Financing Cash Flow(168.1M)(293.6M)(459.6M)(622.6M)(185.1M)
Effect of Forex Changes(15.7M)(10.5M)11.4M(21.4M)22.9M
Net Change in Cash147.1M131.7M(40.4M)(369.3M)306.7M
Free Cash Flow330.6M439.4M414.5M276.4M468.9M

West Pharmaceutical Services, Inc.

NYSE:WST

Intrinsic Alpha fair value

Locked

Current Price

$404.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.